Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor

Deregulation of the cyclin‐dependent kinases (CDKs) has been implicated in the pathogenesis of multiple cancer types. Consequently, CDKs have garnered intense interest as therapeutic targets for the treatment of cancer. We describe herein the molecular and cellular effects of CCT068127, a novel inhi...

Full description

Bibliographic Details
Main Authors: Steven R. Whittaker, Clare Barlow, Mathew P. Martin, Caterina Mancusi, Steve Wagner, Annette Self, Elaine Barrie, Robert Te Poele, Swee Sharp, Nathan Brown, Stuart Wilson, Wayne Jackson, Peter M. Fischer, Paul A. Clarke, Michael I. Walton, Edward McDonald, Julian Blagg, Martin Noble, Michelle D. Garrett, Paul Workman
Format: Article
Language:English
Published: Wiley 2018-03-01
Series:Molecular Oncology
Subjects:
ABT263
CCT068127
CDK
MCL1
seliciclib
Online Access:https://doi.org/10.1002/1878-0261.12148

Internet

https://doi.org/10.1002/1878-0261.12148

Similar Items